TriSalus Life Sciences (NASDAQ:TLSI) Earns Outperform Rating from Analysts at Northland Securities

Northland Securities assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report released on Friday morning, Marketbeat reports. The brokerage issued an outperform rating and a $12.50 price objective on the stock.

TLSI has been the topic of a number of other research reports. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of TriSalus Life Sciences in a report on Thursday, June 27th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Buy” and a consensus price target of $12.50.

TriSalus Life Sciences Stock Down 1.0 %

Shares of NASDAQ TLSI opened at $4.07 on Friday. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42. The firm has a market cap of $119.29 million, a P/E ratio of -1.63 and a beta of 0.47. The business’s 50 day moving average price is $4.74 and its 200 day moving average price is $6.43.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million for the quarter. As a group, research analysts expect that TriSalus Life Sciences will post -1.53 earnings per share for the current year.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $5.20 per share, with a total value of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares in the company, valued at approximately $1,962,386.40. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $1,184,000. Finally, Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $240,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.